 NEW YORK, Sept. 27, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS disorders, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient through Community-based Collaboration at the 5th Pharma Pricing, Reimbursement Market Access 2021 conference on Wednesday, September 29th at 2:40 pm ET. 